LED said its FDA-approved VELscope Vx product will now be available directly through the company.
By utilzing tissue fluorescence visualization technology, theVELscope Vx device detects early stage oral cancer, pre-cancer, and other abnormalities in the mouth such as viral, fungal and bacterial infections.
LED founder and CEO Peter Whitehead said the company believes that its marketing and distribution efforts will be more profitably conducted through a variety of channels.
"Besides potentially increasing the return on sales to LED, taking greater control of our distribution will give us the opportunity to fine-tune our marketing and distribution plans as we capitalize on the success of our domestic and international sales campaigns," Whitehead added.
